BSF Enterprise Plc
Research BSF Enterprise Plc (BSFA) on Bullrun: market cap GBX 229.33M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBSFA
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 229.33M
- Financial periodFY2025
- RevenueGBP 52.84K
- Revenue growth-8.6%
- Net income-GBP 1.11M
- Free cash flow-GBP 1.02M
- Gross margin-34.4%
Valuation Snapshot
latest market cap is GBX 229.33M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 52.84K | -GBP 1.11M | -GBP 1.02M | -34.4% | -0.01 | GBP 149.02K | GBP 0 | GBP 2.72M |
| FY2024 | GBP 57.82K | -GBP 1.67M | -GBP 1.60M | -46.1% | -0.02 | GBP 637.66K | GBP 78.05K | GBP 3.19M |
| FY2023 | GBP 12.94K | -GBP 1.50M | -GBP 1.44M | -451.1% | -0.02 | GBP 2.32M | GBP 156.93K | GBP 4.86M |
| FY2022 | GBP 0 | -GBP 930.04K | -GBP 677.86K | n/a | -0.02 | GBP 1.06M | GBP 231.88K | GBP 3.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-29 | GBX 229.33M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About BSF Enterprise Plc
BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BSF Enterprise Plc's market cap?
BSF Enterprise Plc's market capitalization is GBX 229.33M.
What does BSF Enterprise Plc do?
BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.